Compare · COSM vs PETQ
COSM vs PETQ
Side-by-side comparison of Cosmos Health Inc. (COSM) and PetIQ Inc. (PETQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COSM and PETQ operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COSM carries a market cap of $30.2M.
- COSM has hit the wire 9 times in the past 4 weeks while PETQ has been quiet.
- PETQ has more recent analyst coverage (8 ratings vs 0 for COSM).
- Company
- Cosmos Health Inc.
- PetIQ Inc.
- Price
- -
- -
- Market cap
- $30.2M
- -
- 1M return
- -3.57%
- -
- 1Y return
- -61.25%
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 9
- 0
- Recent ratings
- 0
- 8
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
PetIQ Inc.
PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Latest COSM
- Cosmos Health's CosmoFarm Begins Commissioning New Automated Order-Processing and Vehicle-Loading Infrastructure, Advancing Capacity That Could Support Over $120 Million in Annual Revenue
- Cosmos Health's Amazon UK Business Surpasses $2 Million in TTM Sales, Up 90%, with a 23% Net Profit Margin; Expects Sales to Grow Approximately 72% to $3.9 Million Over the Next Twelve Months
- SEC Form SCHEDULE 13G filed by Cosmos Health Inc.
- Cosmos Health's U.S. Active Subscriptions Surpass 12,000, Up 92% in Two Weeks
- Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target
- Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway
- SEC Form 8-K filed by Cosmos Health Inc.
- Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion
- Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days
- Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
Latest PETQ
- PetIQ Names Camillo Pane as Chief Executive Officer
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- SEC Form 15-12G filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, GENERAL COUNSEL Carter William J. returned 3,497 shares to the company, closing all direct ownership in the company (SEC Form 4)